Jan 25, 2024 · TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the …

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb …

Jun 27, 2024 · Dupilumab resulted in histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo. The higher-exposure dupilumab regimen …

Sep 11, 2025 · Dupixent for EOE Side Effects While Dupixent for eosinophilic esophagitis is generally well tolerated, side effects most often include injection-site reactions, upper …

The Disease Eosinophilic esophagitis (EoE) is a long-term, inflammatory disease of the esophagus, affecting children and adults In children, it causes symptoms such as vomiting, …

Dec 21, 2022 · Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a …

Jan 25, 2024 · 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these …

Dec 11, 2024 · Long-term management options for EoE have remained a significant unmet need in the field. This study bridges that gap by demonstrating that weekly 300 mg dupilumab is well …

Jul 25, 2025 · For investors, this study could impact Regeneron and Sanofi’s stock performance by potentially expanding the market for DUPIXENT® if successful outcomes are reported. The …

Feb 21, 2024 · The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the …